Vitamin D Testing and Treatment for COVID 19 : Vitamin D Testing and Treatment for Adults With COVID 19
Protocol for Part 1:A single blood draw at SCNM to measure levels of vitamin D and other nutrients, comprehensive metabolic panel, and complete blood count with differentialCompleting a medical history/symptom formCompleting a form about COVID-19 symptoms every 2 weeks for 6 weeksAuthorization for release of medical records related to COVID 19 testing and/or treatment.Protocol for Part 2:Take a vitamin D supplement daily for two weeks, at a dosage of 10,000 IU/day b.i.d. (age 18-69 years) or 15,000 IU/day t.i.d. (age 70+)After two weeks of taking vitamin D, return to SCNM for a blood draw to remeasure levels of vitamin D, comprehensive metabolic panel, and complete blood count with differential. If vitamin D levels are still below 30 ng/ml, continue the dosage for 3 more weeks. If vitamin D levels are 30-49 ng/ml, continue at a dosage of 5000 IU/day. If vitamin D levels are 50+ ng/ml, stop supplementation.Completing questionnaires about COVID 19 symptoms at 2, 4, and 6 weeks after treatment begins (5 minutes each time)..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
ClinicalTrials.gov - (2021) vom: 30. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: May 29, 2020, Last downloaded: ClinicalTrials.gov processed this data on January 10, 2022, Last updated: January 12, 2022 |
|---|
| Study ID: |
NCT04407286 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG003406334 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG003406334 | ||
| 003 | DE-627 | ||
| 005 | 20230425190948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG003406334 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04407286 | ||
| 035 | |a (UBBS_Klinische_Studien)STUDY00011960 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Vitamin D Testing and Treatment for COVID 19 |b Vitamin D Testing and Treatment for Adults With COVID 19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: May 29, 2020, Last downloaded: ClinicalTrials.gov processed this data on January 10, 2022, Last updated: January 12, 2022 | ||
| 520 | |a Protocol for Part 1:A single blood draw at SCNM to measure levels of vitamin D and other nutrients, comprehensive metabolic panel, and complete blood count with differentialCompleting a medical history/symptom formCompleting a form about COVID-19 symptoms every 2 weeks for 6 weeksAuthorization for release of medical records related to COVID 19 testing and/or treatment.Protocol for Part 2:Take a vitamin D supplement daily for two weeks, at a dosage of 10,000 IU/day b.i.d. (age 18-69 years) or 15,000 IU/day t.i.d. (age 70+)After two weeks of taking vitamin D, return to SCNM for a blood draw to remeasure levels of vitamin D, comprehensive metabolic panel, and complete blood count with differential. If vitamin D levels are still below 30 ng/ml, continue the dosage for 3 more weeks. If vitamin D levels are 30-49 ng/ml, continue at a dosage of 5000 IU/day. If vitamin D levels are 50+ ng/ml, stop supplementation.Completing questionnaires about COVID 19 symptoms at 2, 4, and 6 weeks after treatment begins (5 minutes each time). | ||
| 650 | 2 | |a COVID-19 | |
| 650 | 2 | |a Vitamin D Deficiency | |
| 650 | 4 | |a Medical Condition: Covid 19, Vitamin D Deficiency | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Completed | |
| 650 | 4 | |a Phase: Phase 1 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2021) vom: 30. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:30 |g month:12 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04407286 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 30 |c 12 | ||